PRELAJ, ARSELA

PRELAJ, ARSELA  

DIPARTIMENTO DI ELETTRONICA, INFORMAZIONE E BIOINGEGNERIA  

Mostra records
Risultati 1 - 20 di 36 (tempo di esecuzione: 0.043 secondi).
Titolo Data di pubblicazione Autori File
Abstract PO-065: Artificial intelligence to improve selection for NSCLC patients treated with immunotherapy 1-gen-2021 Prelaj, ArselaRestelli, MarcelloPedrocchi, AlessandraTrovo, Francesco +
ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients? 1-gen-2020 Prelaj A. +
Beyond first-line immunotherapy: Potential therapeutic strategies based on different pattern progressions: Oligo and systemic progression 1-gen-2021 Prelaj A. +
Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma 1-gen-2021 Prelaj, Arsela +
Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation 1-gen-2022 Prelaj, ArselaManglaviti, Sara +
Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis 1-gen-2021 Prelaj A. +
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy 1-gen-2019 Prelaj A. +
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out 1-gen-2019 Prelaj A. +
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer 1-gen-2022 Prelaj, Arsela +
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non–Small-Cell Lung Cancer: An External Validation 1-gen-2020 Prelaj A. +
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer 1-gen-2019 Prelaj A. +
Epsilon: A prognostic score for immunotherapy in advanced non-small-cell lung cancer: A validation cohort 1-gen-2019 Prelaj A. +
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy 1-gen-2020 Prelaj A. +
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors 1-gen-2021 Prelaj, Arsela +
Exploring the role of respiratory microbiome in lung cancer: A systematic review 1-gen-2021 Prelaj, Arsela +
Gastrointestinal stromal tumors and second primary malignancies: a retrospective monocentric analysis 1-gen-2020 Prelaj, A +
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 1-gen-2022 Prelaj, Arsela +
Immunotherapy beyond progression in patients with advanced non-small cell lung cancer 1-gen-2020 Prelaj A. +
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers 1-gen-2021 Prelaj A. +
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system 1-gen-2020 Prelaj, AGalli, GTrovo, F +